Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum no. 14
- Development stage
- Preclinical
- Lead developer
- Meiji
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum No. 14 (recently reclassified as *Lactiplantibacillus plantarum* No. 14) is a specific probiotic strain investigated for its potential therapeutic effects on metabolic disorders. Research in animal models, including diet-induced obese C57BL/6 mice and KK/Ta mice (a model for type 2 diabetes), has demonstrated that oral administration of this strain can significantly reduce white adipose tissue (WAT) accumulation and adipocyte size. The strain appears to improve insulin sensitivity, as evidenced by lower HOMA-IR scores and reduced serum insulin and leptin concentrations. Mechanistically, it has been shown to downregulate the expression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and monocyte chemoattractant protein-1 (MCP-1), particularly in mesenteric adipose tissue, suggesting an anti-inflammatory component to its anti-obesity effects.
- Other names
- L. plantarum No. 14Lactiplantibacillus plantarum No. 14
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))CCL2 (C-C motif chemokine 2)IL-6 (Interleukin 6)
Beyond the preview
Go deeper on lactobacillus plantarum no. 14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum no. 14.